The European Medicines Agency (EMA) says that they have not assessed the report from the research group at Rikshospitalet on the connection between AstraZeneca and blood clots.
On Thursday, the EMA gave the vaccine the green light after investigating possible connections with blood clots.
Norwegian researchers, led by Pål André Holme at Rikshospitalet, concluded on Thursday that such a connection existed.
“We have considered everything that was available until yesterday, so if something more has come today, it is not included. But we have assessed the Norwegian conditions before.
Norwegian recent research not assessed
“If there is a study that has come out today, we have not evaluated it yet. But it will be part of our monitoring of the situation. This is a temporary conclusion,” Sabine Strauss, chair of the EMA’s audit’s safety committee, noted.
The Norwegian Medicines Agency told the newspaper VG that the EMA has not been able to assess the Norwegian results from chief physician and professor Pål André Holme at Rikshospitalet.
“We have sent Holme’s theories to our representatives in PRAC (the adverse reaction committee in the EMA) today,” Sigurd Hortemo in the Norwegian Medicines Agency told the newspaper on Thursday afternoon.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at [email protected]
Be the first to comment on "EMA: The conclusion of Norwegian researchers about AstraZeneca’s connection to blood clots has not been assessed"